Electrophysiological Biomarkers in Genetic Epilepsies

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2021 Oct 13

PMID 34642905

Citations 3

Authors

Caren Armstrong

Eric D Marsh

Affiliations

Soon will be listed here.

Abstract

Precision treatments for epilepsy targeting the underlying genetic diagnoses are becoming a reality. Historically, the goal of epilepsy treatments was to reduce seizure frequency. In the era of precision medicine, however, outcomes such as prevention of epilepsy progression or even improvements in cognitive functions are both aspirational targets for any intervention. Developing methods, both in clinical trial design and in novel endpoints, will be necessary for measuring, not only seizures, but also the other neurodevelopmental outcomes that are predicted to be targeted by precision treatments. Biomarkers that quantitatively measure disease progression or network level changes are needed to allow for unbiased measurements of the effects of any gene-level treatments. Here, we discuss some of the promising electrophysiological biomarkers that may be of use in clinical trials of precision therapies, as well as the difficulties in implementing them.

Citing Articles

A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome.

Campbell K, Neul J, Lieberman D, Berry-Kravis E, Benke T, Fu C J Neurodev Disord. 2025; 17(1):4.

PMID: 39856538 PMC: 11761732. DOI: 10.1186/s11689-025-09591-y.

Quantitative EEG biomarkers for STXBP1-related disorders.

Cossu A, Furia F, Proietti J, Ancora C, Reale C, Darra F Epilepsia. 2024; 65(12):3595-3606.

PMID: 39463124 PMC: 11647438. DOI: 10.1111/epi.18154.

The regulatory function of lncRNA and constructed network in epilepsy.

Kuang S, Wang J, Wei Z, Zhai F, Liang S Neurol Sci. 2023; 44(5):1543-1554.

PMID: 36781564 DOI: 10.1007/s10072-023-06648-5.

Precision Treatments in Epilepsy.

Demarest S, Brooks-Kayal A Neurotherapeutics. 2021; 18(3):1429-1431.

PMID: 34704188 PMC: 8608958. DOI: 10.1007/s13311-021-01147-x.

References

Day J, Finkel R, Chiriboga C, Connolly A, Crawford T, Darras B . Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021; 20(4):284-293. DOI: 10.1016/S1474-4422(21)00001-6. View

Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczynski D, Kmiec T . Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013; 17(5):479-85. DOI: 10.1016/j.ejpn.2013.03.002. View

Rinaldi C, Wood M . Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2017; 14(1):9-21. DOI: 10.1038/nrneurol.2017.148. View

Key A, Jones D, Peters S, Dold C . Feasibility of using auditory event-related potentials to investigate learning and memory in nonverbal individuals with Angelman syndrome. Brain Cogn. 2018; 128:73-79. PMC: 6345395. DOI: 10.1016/j.bandc.2018.11.001. View

. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002; 133(4):467-74. DOI: 10.1016/s0002-9394(02)01327-2. View

Youssef E, Berry-Kravis E, Czech C, Hagerman R, Hessl D, Wong C . Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Neuropsychopharmacology. 2017; 43(3):503-512. PMC: 5770759. DOI: 10.1038/npp.2017.177. View

Kimura K, Nomura Y, Segawa M . Middle and short latency somatosensory evoked potentials (SEPm, SEPs) in the Rett syndrome: chronological changes of cortical and subcortical involvements. Brain Dev. 1992; 14 Suppl:S37-42. View

Numis A, Nair U, Datta A, Sands T, Oldham M, Patel A . Lack of response to quinidine in KCNT1-related neonatal epilepsy. Epilepsia. 2018; 59(10):1889-1898. DOI: 10.1111/epi.14551. View

Zeng L, Xu L, Gutmann D, Wong M . Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008; 63(4):444-53. PMC: 3937593. DOI: 10.1002/ana.21331. View

10.

Sidorov M, Deck G, Dolatshahi M, Thibert R, Bird L, Chu C . Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis. J Neurodev Disord. 2017; 9:17. PMC: 5422949. DOI: 10.1186/s11689-017-9195-8. View

11.

Ness S, Manyakov N, Bangerter A, Lewin D, Jagannatha S, Boice M . JAKE® Multimodal Data Capture System: Insights from an Observational Study of Autism Spectrum Disorder. Front Neurosci. 2017; 11:517. PMC: 5623040. DOI: 10.3389/fnins.2017.00517. View

12.

Erickson C, Davenport M, Schaefer T, Wink L, Pedapati E, Sweeney J . Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord. 2017; 9:7. PMC: 5467059. DOI: 10.1186/s11689-017-9186-9. View

13.

Peters S, Gordon R, Key A . Induced gamma oscillations differentiate familiar and novel voices in children with MECP2 duplication and Rett syndromes. J Child Neurol. 2014; 30(2):145-52. PMC: 4406405. DOI: 10.1177/0883073814530503. View

14.

Roberts T, Khan S, Rey M, Monroe J, Cannon K, Blaskey L . MEG detection of delayed auditory evoked responses in autism spectrum disorders: towards an imaging biomarker for autism. Autism Res. 2010; 3(1):8-18. PMC: 3099241. DOI: 10.1002/aur.111. View

15.

Saunders K, McCulloch D, Kerr A . Visual function in Rett syndrome. Dev Med Child Neurol. 1995; 37(6):496-504. DOI: 10.1111/j.1469-8749.1995.tb12037.x. View

16.

Hagerman R, Jacquemont S, Berry-Kravis E, Portes V, Stanfield A, Koumaras B . Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Sci Rep. 2018; 8(1):16970. PMC: 6242849. DOI: 10.1038/s41598-018-34978-4. View

17.

Azeem A, Kirton A, Appendino J, Kozlik S, Mineyko A . Automated quantification of spike-wave activity may be used to predict the development of electrical status epilepticus in sleep (ESES) in children with perinatal stroke. Clin Neurophysiol. 2020; 132(1):146-153. DOI: 10.1016/j.clinph.2020.11.003. View

18.

Keogh C, Pini G, Dyer A, Bigoni S, DiMarco P, Gemo I . Clinical and genetic Rett syndrome variants are defined by stable electrophysiological profiles. BMC Pediatr. 2018; 18(1):333. PMC: 6195747. DOI: 10.1186/s12887-018-1304-7. View

19.

French J, Lawson J, Yapici Z, Ikeda H, Polster T, Nabbout R . Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016; 388(10056):2153-2163. DOI: 10.1016/S0140-6736(16)31419-2. View

20.

Berry-Kravis E, Horrigan J, Tartaglia N, Hagerman R, Kolevzon A, Erickson C . A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatr Neurol. 2020; 110:30-41. DOI: 10.1016/j.pediatrneurol.2020.04.019. View